Agendia's private party

Dutch molecular diagnostics play Agendia B.V. expects to use this year's largest European venture capital round to reach breakeven.

The company raised $65 million last week in an equity financing led by Debiopharm Group. Last June, Agendia pulled an IPO on NYSE Euronext in Amsterdam. The company had hoped to raise €75 million ($110 million)...